Ann: CEO Address at FY21 A G M, page-28

Excited for the decisions being made and how my investment in IHL is playing out but that meeting with its sudden end and lack of any Q&A was very different to other biotech meetings where management were very accessible to SHs, answered what they could and didn't just read out the prepared statement.

Missed the very start of the meeting, but felt quite rushed the way they (was it Joel?) read through the statement.
Moving forward having an IR company to assist would make these look a lot more professional.